Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock

Key Points

• Insmed CEO William Lewis sold 10,699 shares on April 16 at an average price of $143.97 for about $1.54 million, executing the trade under a pre‑arranged Rule 10b5‑1 plan and reducing his stake to 301,185 shares (a 3.43% drop).
• The April 16 sale is part of a pattern of insider sales since January — totaling roughly 80,599 shares across multiple transactions — indicating systematic, planned dispositions rather than a one‑off sale.
• Insmed stock traded at $144.48 (up ~1.2%); the company reported negative EPS but strong revenue growth, and analysts maintain a consensus "Buy" rating with an average target of $213.23.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the company's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $143.97, for a total value of $1,540,335.03. Following the completion of the sale, the chief executive officer directly owned 301,185 shares of the company's stock, valued at approximately $43,361,604.45. This trade represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

William Lewis also recently made the following trade(s):

• On Monday, April 6th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $163.22, for a total value of $1,746,290.78.
• On Thursday, March 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $143.52, for a total value of $1,535,520.48.
• On Thursday, March 5th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $146.03, for a total value of $1,562,374.97.
• On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $150.97, for a total value of $1,615,228.03.
• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The shares were sold at an average price of $147.79, for a total value of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The shares were sold at an average price of $156.34, for a total value of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total value of $1,700,392.07.

Insmed Trading Up 1.2%

Shares of INSM stock traded up $1.69 on Friday, reaching $144.48. The company had a trading volume of 2,048,436 shares, compared to its average volume of 2,475,861. The company has a 50-day moving average of $150.06 and a 200-day moving average of $167.29. Insmed, Inc. has a 12 month low of $63.81 and a 12 month high of $212.75. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The stock has a market cap of $31.19 billion, a PE ratio of -22.54 and a beta of 1.10.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. During the same period in the previous year, the company posted ($1.32) earnings per share. Insmed's revenue for the quarter was up 152.6% compared to the same quarter last year. On average, equities analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Institutional Investors Weigh In On Insmed

Large investors have recently made changes to their positions in the stock. Norges Bank bought a new position in shares of Insmed in the fourth quarter worth $506,625,000. Vanguard Group Inc. increased its position in shares of Insmed by 13.0% in the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company's stock worth $2,870,957,000 after purchasing an additional 2,291,328 shares during the period. RTW Investments LP increased its position in shares of Insmed by 57.0% in the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company's stock worth $842,855,000 after purchasing an additional 1,758,321 shares during the period. Artisan Partners Limited Partnership increased its position in shares of Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company's stock worth $711,076,000 after purchasing an additional 1,623,342 shares during the period. Finally, Orbis Allan Gray Ltd bought a new position in shares of Insmed in the second quarter worth $153,389,000.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on INSM. Mizuho increased their target price on Insmed from $204.00 to $206.00 and gave the stock an "outperform" rating in a research note on Wednesday, March 25th. Bank of America increased their target price on Insmed from $211.00 to $213.00 and gave the stock a "buy" rating in a research note on Tuesday, March 24th. Barclays increased their target price on Insmed from $231.00 to $237.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 1st. Royal Bank Of Canada increased their target price on Insmed from $212.00 to $216.00 and gave the stock an "outperform" rating in a research note on Tuesday. Finally, Raymond James Financial began coverage on shares of Insmed in a research note on Friday, April 10th. They set an "outperform" rating and a $200.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $213.23.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.